INTRODUCTION
============

Infection by *Sphingomonas paucimobilis* is rare. Although it occurs mostly in immunocompromised patients, cases of infected immunocompetents have been reported. We present a case of subperiosteal abscess due to a complicated otomastoiditis in an immunocompetent child. No previous case of subperiosteal abscess or otomastoiditis caused by *S. paucimobilis* has been reported. *S. paucimobilis* infection reports have been increasing in pediatric cases, encouraging us to conduct a literature review accompanied by the analysis of the clinical, demographic, and treatment data of the retrieved pediatric case report. We searched the PubMed and Google Scholar databases using the terms "*Sphingomonas paucimobilis*", "*Pseudomonas paucimobilis*," "Sphingomonas," and "paucimobilis"; checking out the references of each elected article for any paper that could have been missed. All available publications related to *S. paucimobilis* infection in children, from 0 to 18 years, were retrieved.

To the best of our knowledge, this is the first review of pediatric infections due to these bacteria.

CASE REPORT
===========

An 11-year-old boy was brought to the emergency department with a 20-day history of fever, otalgia, otorrhea, and progressive retroauricular swelling, displacing the left ear anteriorly and downwards ([Figure 1](#g01){ref-type="fig"}).

![3D reformation of the mastoid computed tomography showing the bulging tumoral mass displacing the left ear downwards and anteriorly.](autopsy-04-03013-g01){#g01}

He was previously prescribed amoxicillin for 15 days without improvement. He lived in an orphanage and his HIV serology was negative. He had a previous diagnosis of bilateral chronic otitis media, but no other comorbidity was present. A computed tomography (CT) scan was performed ([Figure 2](#g02){ref-type="fig"}) showing left otomastoiditis associated with a large fluid collection involving the subperiosteal layer of the temporal bone and the surrounding soft tissues, measuring 10.1 × 6.0 × 2.2 cm. Blood tests showed a white blood count of 22.4 × 10^3^mm^3^ (reference value \[RV\]: 4.5‑11.0 × 10^3^/mm^3^)(neutrophils 81.2%; RV: 40-70%) and C-reactive protein of 142 mg/L (RV: \< 5 mg/L).

![Computed tomography of the mastoid**. A** and **B** - Coronal plane. **C** and **D** - Axial plane. **D** represents the bone window. Arrow 1 shows the erosion of the temporal bone; arrow 2 the external ear canal. The abscess is connected with the mastoid do to the erosion of the temporal bone. The collection involved all soft tissues of the temporal region limited externally by the skin.](autopsy-04-03013-g02){#g02}

Surgical intervention on the retroauricular mass found a large amount of fetid and purulent secretion, a sample of which was sent off for microbiology studies. Ceftazidime and clindamycin were empirically started. The outcome was successful immediately after the surgical procedure, with fever defervescence, and normalization of blood tests. After 8 days of incubation, the culture of purulent secretion was positive for *S. paucimobilis*, but unfortunately, the antibiogram could not be tested because the bacteria in the culture media was no longer available. Therefore, based on literature data, we decided to maintain the initial antibiotic regimen and discharged the patient on the tenth day of hospitalization, scheduling 10 more days of oral ciprofloxacin to be taken at home.

METHODS
=======

We searched PubMed, Google Scholar and LILACS databases using the terms "Sphingomonas paucimobilis", "Pseudomonas paucimobilis", "Sphingomonas" and "paucimobilis". The references of each selected article were checked out in order to avoid missing any other paper. From a total of 1699 articles, 20 were related to *Sphingomonas paucimobilis* infection in children and adolescents up to 18 years, and therefore were selected.

DISCUSSION
==========

The genus *Sphingomonas* comprises 13 Gram-negative, non-fermentative, non-sporing, oxidase- and catalase-positive bacilli. *Sphingomonas paucimobilis* is slightly motile (thus paucimobilis) and forms yellow pigmented colonies in blood agar.[@B001] It was believed that *S. paucimobilis* was the only specimen of clinical importance; however, recently *Sphingomonas mucosissima* and *Sphingomonas adhesiva* also have been related to human infection.[@B002]^,^[@B003] These bacilli are ubiquitous in nature (especially in water and soil) and in nosocomial environments causing mild-to-severe community and nosocomial illnesses.[@B001]^,^[@B004]

First described by Holmes et al.[@B005] in the 1970s as *Pseudomonas paucimobilis*, it was later reclassified as *Sphingomonas paucimobilis* in accordance with phylogenetic data by Yabuuchi et al.[@B006] in the 1990s. Curiously, this bacteria was related to the death of the coral reef on the coast of Florida, USA.[@B007]

The full-automated microbiology identification systems like "autoSCAN-W/A" and the "Vitek GNI1," may fail to identify some genera and species. Sung et al.[@B008] showed that the major misidentified bacteria were the Gram-negative non-fermentative, especially *S. paucimobilis* in the autoSCAN-W/A system.

In 1979, the case of an infected leg ulcer of a Japanese seaman in Australia, was the first reported human infection.[@B009] In 1981, the first pediatric colonization case by this bacteria was reported,[@B010] but only in 1988 did Tiffany and Kline[@B011] describe the first pediatric case of *S. paucimobilis* infection related to a brain abscess in a 6-year-old boy after a head trauma. Since then, the reports on this infection has increased, totaling 59 reported cases in pediatrics to date. Before 1980, no *S. paucimobilis* infection in children was reported. One case was reported between 1981 and 1990, three cases between 1991 and 2000, 28 cases between 2001 and 2010, and 27 cases between 2011 and March 2014, including ours ([Figure 3](#g03){ref-type="fig"}). Despite the reported cases of infections, numerous cases of colonization by this bacteria were also published.[@B010]^,^[@B012]^,^[@B013]

![The number of reported pediatric cases of *S. paucimobilis* infection from 1980 until March 2014.](autopsy-04-03013-g03){#g03}

[Table 1](#t01){ref-type="table"} lists all elected cases of pediatric *S. paucimobilis* infection retrieved in our review. [Table 2](#t02){ref-type="table"} summarizes the demographic and clinical data. The median age was 4.4 years (ranging from 3 days to 17 years); 22 cases occurred during the neonatal period (37.3%). The observed male:female ratio was 1.7:1.0. Hospital-acquired disease was identified in 66.1% and previous comorbidities were present in all of those patients.

###### Cases of *S. paucimobilis* infection in children, since the first publication in 1988 until March 2014

  Condition                                    Age    Gender   Underlying conditions       Therapy                                 Country          Source of outbreak                   Number of patients   Reference
  -------------------------------------------- ------ -------- --------------------------- --------------------------------------- ---------------- ------------------------------------ -------------------- ---------------
  CR-BSI                                       14y    \-       Acute myeloid leukemia      Trimethoprim-Sulfamethoxazole           Saudi Arabia     Hospital                             1                    14
  Osteomyelitis/ septic arthritis              16y    M        ALL                         Amikacin/Ceftazidime                    United Kingdom   [\*\*](#TFN2){ref-type="table-fn"}   1                    15
  Bacteremia                                   \<1y   F        Chylothorax                 Not described                           Korea            Hospital                             1                    16
  Bacteremia                                   2y     F        Aplastic anemia             Not described                           Korea            Hospital                             1                    16
  Bacteremia                                   8y     M        ALL                         Not described                           Korea            Hospital                             1                    16
  Bacteremia                                   \<1y   M        Neonatal sepsis             Not described                           Korea            Hospital                             1                    16
  CAPD peritonitis                             14y    F        End-stage renal disease     Not described                           Korea            Hospital                             1                    16
  CR-BSI                                       1y     M        Anaplastic ependymoma       Not described                           Korea            Hospital                             1                    16
  CR-BSI                                       17y    M        Ewing sarcoma               Not described                           Korea            Hospital                             1                    16
  CR-BSI                                       10d    M        Prematurity/RDS             Not described                           Taiwan           Hospital                             1                    17
  Bacteremia                                   6y     F        Lymphoma                    Imipenem/Teicoplanin                    Turkey           Hospital                             1                    18
  Bacteremia                                   5y     F        Neuroblastoma               Imipenem/Teicoplanin                    Turkey           Hospital                             1                    18
  Bacteremia                                   11y    M        Non-Hodgkin lymphoma        Imipenem/Teicoplanin                    Turkey           Hospital                             1                    18
  Bacteremia                                   3y     M        Acute myeloid leukemia      Imipenem/Teicoplanin                    Turkey           Hospital                             1                    18
  Pneumonia                                    5y     M        None                        Ampicillin-Sulbactam                    Taiwan           Community                            1                    19
  UTI                                          5m     M        None                        Ampicillin/Gentamicin                   Taiwan           Community                            1                    19
  Bacteremia[\*](#TFN1){ref-type="table-fn"}   0m     \-       Prematurity                 Not described                           Turkey           Hospital                             13                   20
  Bacteremia                                   2y     M        None                        Ceftriaxone                             India            Community                            1                    20
  Bacteremia                                   7y     F        None                        Cefuroxime                              Turkey           Community                            1                    22
  Bacteremia                                   1m     F        None                        Ampicillin/Sulbactam                    Turkey           Community                            1                    22
  Bacteremia                                   15y    F        None                        Cefotaxime                              Turkey           Community                            1                    22
  Bacteremia                                   1y     F        None                        Cefuroxime                              Turkey           Community                            1                    22
  Bacteremia                                   8y     F        Neutropenia-ALL             Piperacillin/Tazobactam                 Turkey           Hospital                             1                    22
  Bacteremia                                   8d     F        Prematurity                 Meropenem/Vancomycin                    Turkey           Hospital                             1                    22
  Bacteremia                                   12y    F        None                        Piperacillin/Tazobactam                 Turkey           Hospital                             1                    22
  Bacteremia                                   27d    F        None                        Meropenem                               Turkey           Hospital                             1                    22
  Bacteremia                                   3y     M        None                        Cefotaxime                              Turkey           Community                            1                    22
  Bacteremia                                   12y    M        PSAGN                       Cefuroxime                              Turkey           Community                            1                    22
  Bacteremia                                   18d    M        Prematurity                 Ampicillin/Amikacin                     Turkey           Community                            1                    22
  Bacteremia                                   9y     M        Down syndrome               Meropenem/Vancomycin                    Turkey           Community                            1                    22
  Bacteremia                                   1m     M        None                        Ampicillin/Sulbactam                    Turkey           Community                            1                    22
  Bacteremia                                   3d     M        None                        Ampicillin/Amikacin                     Turkey           Community                            1                    22
  Bacteremia                                   23d    M        None                        Ampicillin/Sulbactam                    Turkey           Community                            1                    22
  Bacteremia                                   1y     M        Imperforate anus            Ceftazidime                             Turkey           Hospital                             1                    22
  Bacteremia                                   23d    M        Duodenal atresia            Cefotaxime/Amikacin                     Turkey           Hospital                             1                    22
  Bacteremia                                   11y    M        None                        Meropenem                               Turkey           Hospital                             1                    22
  Bacteremia                                   4y     M        Neutropenia-ALL             Piperacillin/Tazobactam                 Turkey           Hospital                             1                    22
  Bacteremia                                   5y     M        Neutropenia-ALL             Piperacillin/Tazobactam                 Turkey           Hospital                             1                    22
  CNS infection                                10y    M        None                        Cefotaxime/Vancomycin                   Turkey           Community                            1                    22
  CR-BSI                                       4y     M        Burn injury                 Meropenem/Amikacin                      Turkey           Hospital                             1                    22
  CR-BSI                                       10y    F        Neutropenia-ALL             Piperacillin/Tazobactam                 Turkey           Hospital                             1                    22
  UTI                                          4m     F        None                        Cefuroxime                              Turkey           Community                            1                    22
  Bacteremia                                   1y     M        Cardiopathy-Down syndrome   Piperacillin/Tazobactam                 Turkey           Hospital                             1                    4
  Otomastoiditis                               11y    M        None                        Ceftazidime/Clindamycin/Ciprofloxacin   Brazil           Community                            1                    Present Study
  Bacteremia                                   6y     M        None                        Cefotaxime/Gentamicin                   Spain            Community                            1                    23
  Cervical adenitis                            8y     M        None                        Ampicillin                              Spain            Community                            1                    23
  Brain abscess                                6a     F        None                        Ampicillin/Chloramphenicol              USA              Community                            1                    11

ALL = acute lymphoblastic leukemia); CAPD = continuous ambulatory peritoneal dialysis; CNS = central nervous system; CR-BSI = catheter-related bloodstream infection; PSAGN = steroid-induced immunosuppression due to glomerulonephritis; RDS = respiratory distress syndrome; UTI = urinary tract infection;

= case of fatal outcome;

= the author could not define if it was a community or hospital infection.

###### Demographic and clinical characteristics of *S. paucimobilis* infection in children---data of the literature review

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Condition                                             No. of cases   Mean age (range)   Gender\       Healthy/previous\   Nosocomial/Community-acquired\
                                                                                          (ratio) M:F   comorbidity\        (No. of cases)
                                                                                                        (no. of cases)      
  ----------------------------------------------------- -------------- ------------------ ------------- ------------------- --------------------------------------
  Isolated bacteremia[\*](#TFN3){ref-type="table-fn"}   44             3.1y (0-15y)       1.5:1         13/31               31/13

  CR-BSI                                                6              8.3y (0-17y)       4:1           0/6                 6/0

  UTI                                                   2              4.5m (4-5m)        1:1           2/0                 0/2

  CAPD peritonitis                                      1              14y                0:1           0/1                 1/0

  Cervical adenitis                                     1              8y                 1:0           1/0                 0/1

  CNS infection                                         1              10y                1:0           1/0                 1/0

  CNS abscess                                           1              6y                 0:1           1/0                 0/1

  Osteomyelitis/septic arthritis                        1              16y                1:0           0/1                 [\*\*\*](#TFN5){ref-type="table-fn"}

  Pneumonia                                             1              5y                 1:0           1/0                 0/1

  Otomastoiditis[\*\*](#TFN4){ref-type="table-fn"}      1              11y                1:0           1/0                 0/1

  Total                                                 59             4.4y (0-17y)       1.7:1         20/39               39/20
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

CAPD = continuous ambulatory peritoneal dialysis; CNS = central nervous system; CR-BS = catheter-related bloodstream infection; UTI = urinary tract infection;

= case of fatal outcome;

= present study;

= the author could not define if it was nosocomial or community acquired infection.

The most common infection site was primary bacteremia (74.6%) followed by catheter-related bloodstream infection (10.2%), urinary tract infection (3.4%) and one case (1.7%) of each of the following: peritonitis related to continuous ambulatory peritoneal dialysis, cervical adenitis, central nervous system (CNS) infection, CNS abscess, osteomyelitis/septic arthritis, pneumonia, and otomastoiditis. Prematurity was the commonest associated comorbidity observed in 16 cases (41%); 13 cases were associated with malignancy (33%), out of which all were from the hematopoietic system; 2 cases (5.2%) occurred in children with Down syndrome, 2 cases (5.2%) with gut malformations, and 6 cases associated with other isolated diseases.

*S. paucimobilis* has been isolated from blood, sputum, urine, wound, ascitic liquid, cerebrospinal fluid, synovial liquid, and purulent secretion (brain, bone, and mastoid).[@B011]^,^[@B014]^-^[@B023]

Some studies associate *S. paucimobilis* outbreaks with contamination of the nosocomial environment; however, none of the reviewed papers demonstrated the same strain of the contamination with those of the infection site.[@B017]^,^[@B018]^,^[@B020]^,^[@B024] Consequently, the endogenous source of the infection is the current theory on the route of infection.[@B017]^,^[@B023] In addition, infection was also related to hospitalization, indwelling devices, and previous comorbidities, but our own case and other recent studies show that community-acquired infections are more prevalent than previously thought.[@B019]^,^[@B025]

Although Gram-negative infections frequently result in significant morbidity and mortality, *S. paucimobilis* infections seem to show a low rate of complications and a favorable prognosis.[@B016]^,^[@B019]^,^[@B021]^,^[@B024]^,^[@B025] Only one case of pediatric death has been reported related to *S. paucimobilis* infection, which occurred in a premature neonate with septic shock.[@B020] It is supposed that this low virulence is caused by the presence of atypical lipopolysaccharide in the outer membrane, a deficiency of bacterial endotoxins, and a different enzyme profile.[@B006]^,^[@B026]^,^[@B027]

*S. paucimobilis* antibiotic susceptibility varies according to the study. In general, they are significantly resistant to cephalosporin, especially the third generation, as well as to penicillins. Lin et al.19 showed that all isolated bacteria produced β-lactamase; however, other studies showed a resistance to cephalosporins of around 20%.21,22 There is also reported resistance to aminoglycosides, quinolones, trimethoprim, and sulfamethoxazole, and lesser to carbapenems.[@B004]^,^[@B014]^-^[@B018]^,^[@B021]^,^[@B022] In previous studies, the recommendation of initial antibiotic therapy was a third generation cephalosporin added to an aminoglycoside; however, more current studies suggest that carbapenems or quinolones show a better susceptibility pattern.[@B004]^,^[@B016]^,^[@B017]^,^[@B022]

Despite supposed initial inappropriate antibiotic therapy reported in some cases of the literature, none presented any complication due to the delayed institution of the appropriate treatment.[@B021]^,^[@B022] Since antibiotic resistance varies, treatment should be guided by the susceptibility test results of each case.[@B004]^,^[@B016]

In conclusion, *S. paucimobilis* is an emerging pathogen in pediatric patients, and not just a contaminant of the hospital environment. The nosocomial or community-acquired infection is related to previous comorbidities, which are mostly associated with immunosuppression due to prematurity and malignancy. However, previously healthy patients may also be involved. Compared with other Gram-negative bacteria, *S paucimobilis,* characteristically present low virulence; however, death has been reported already in one pediatric case. Notwithstanding the resistance to beta-lactam antibiotics, the first choice of treatment consists in carbapenems or quinolones.
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